A persistent clinical problem. Bladder cancer is the second most common genitourinary cancer worldwide, with approximately 430,000 new cases diagnosed globally in 2012. Despite decades of treatment, the five-year survival rate remains low, and the recurrence rate -- between 30% and 70% depending on disease stage -- is the highest of any cancer type.
Stagnant treatment progress. Treatment approaches for bladder cancer have changed little over the past 30 years. Transurethral resection remains the primary procedure for non-muscle-invasive disease, but recurrence is common, and 30% of cases progress to muscle-invasive disease requiring more aggressive intervention. New biomarkers are urgently needed to improve diagnosis, prognosis prediction, and treatment selection.
Immunotherapy as an emerging opportunity. Checkpoint inhibitor drugs targeting PD-1 and PD-L1 have shown promise across multiple cancers, and BCG immunotherapy has long been used for bladder cancer. However, biomarkers that predict which patients will respond to immunotherapy -- and that may themselves represent new immunotherapy targets -- have been largely lacking for bladder cancer.
Multi-database integration for reliable discovery. Gene expression studies using single datasets are prone to false positives and may reflect dataset-specific artifacts. By integrating data from multiple independent sources -- two GEO datasets and the TCGA -- and requiring that candidate genes appear consistently across all three, this study aimed to identify more reliable bladder cancer biomarkers.
Three gene expression datasets. The study integrated data from GSE7476 (9 bladder cancer samples and 3 normal samples), GSE13507 (188 bladder cancer and 68 normal samples), and TCGA BLCA (404 cancer and 19 normal samples). Differentially expressed genes (DEGs) were identified in each dataset separately using logFC greater than 1 or less than -1 and P less than 0.05 as thresholds, then overlapping DEGs across all three datasets were selected for downstream analysis.
Functional enrichment analysis. GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analyses were performed using both Metascape and DAVID online tools to understand what biological processes and molecular pathways the DEGs are involved in. Analysis was conducted from three perspectives: biological processes (BP), cellular components (CC), and molecular functions (MF).
Protein-protein interaction network analysis. All overlapping DEGs were entered into the STRING database to build a protein-protein interaction (PPI) network. Cytoscape software was used to visualize the network, and the cytoHubba plugin identified central 'hub' genes using four different scoring algorithms: DEGREE, MCC, DMNC, and MNC. Genes ranked highly by all four methods were considered high-confidence hub genes.
Survival analysis for target gene selection. Hub gene expression levels from TCGA data were correlated with bladder cancer patient survival using the Human Protein Atlas and GEPIA tools. Only hub genes where high expression was significantly associated with worse survival outcomes were prioritized as target genes. Immune infiltration and immune checkpoint correlations were subsequently analyzed using the TIMER database.
Starting pool of 291 DEGs. After intersecting the differentially expressed genes from all three datasets, 50 upregulated and 241 downregulated genes were consistently altered in bladder cancer compared to normal tissue. Upregulated genes included well-known cell cycle regulators (CDC20, TTK, AURKA, AURKB, TOP2A) and cell division proteins (ASPM, CEP55, KIF20A), while downregulated genes included extracellular matrix components and smooth muscle proteins.
Pathway enrichment reveals cell cycle and immune involvement. GO analysis showed DEGs were enriched in mitotic sister chromatid segregation, cell division, M-phase processes, and cytoskeleton organization. KEGG analysis highlighted focal adhesion, arachidonic acid metabolism, and vascular smooth muscle contraction. REACTOME analysis revealed enrichment in immune system signaling, muscle contraction, hemostasis, and biological oxidations.
14 hub genes identified by multi-method consensus. Applying all four cytoHubba hub gene identification algorithms to the PPI network yielded 14 consensus hub genes: ASPM, CCNB2, CDC20, CENPF, CEP55, HJURP, KIF20A, NCAPG, NUSAP1, SPAG5, TOP2A, TRIP13, TROAP, and TTK. All 14 were significantly upregulated in bladder cancer tissue compared to normal bladder tissue in TCGA analysis.
Survival analysis narrows the list. Of the 14 hub genes, survival analysis using the Human Protein Atlas identified CDC20 and ASPM as the genes where high expression most significantly predicted poor prognosis in bladder cancer patients. These two genes were selected as primary target genes for further investigation.
Pan-cancer upregulation. Analysis through the TIMER database showed CDC20 is significantly upregulated not only in bladder cancer but across 17 different cancer types including breast, colorectal, esophageal, head and neck, kidney, liver, lung, stomach, thyroid, and endometrial cancers. This broad pattern suggests CDC20 plays a fundamental role in cancer biology across tissue types.
Expression varies by clinical features. UALCAN analysis confirmed high CDC20 expression in bladder cancer, with further differential expression based on patients' smoking habits, histological subtypes, and molecular subtypes. Additionally, CDC20 expression was inversely correlated with promoter methylation levels, suggesting epigenetic regulation of this gene in bladder cancer.
Cell cycle pathway dominates CDC20 biology. Protein-protein interaction analysis identified CDC20's ten most correlated genes (BUB1, BUB3, BUB1B, CCNA2, CCNB1, MAD2L1, PLK1, and PTTG1), and KEGG pathway analysis of this network showed enrichment primarily in cell cycle regulation, oocyte meiosis, and progesterone-mediated oocyte maturation. CDC20 is a key activator of the anaphase-promoting complex that drives cells through mitosis, and its overexpression can accelerate uncontrolled cell division.
Immune checkpoint coexpression. CDC20 showed significant coexpression with all five immune checkpoint genes analyzed: PDCD1 (PD-1), CD274 (PD-L1), PDCD1LG2 (PD-L2), TOX, and CTLA4. This unexpected link between a cell cycle regulator and immune checkpoint machinery suggests CDC20 expression may influence immune evasion in bladder cancer beyond its established role in cell division.
Pan-cancer expression pattern. Like CDC20, ASPM (abnormal spindle microtubule assembly) was found to be significantly upregulated across the same 17 cancer types in TIMER analysis. ASPM was originally identified as a gene mutated in primary microcephaly, but its overexpression in cancer suggests a role in promoting aberrant cell division.
Clinical feature associations. ASPM expression in bladder cancer varied significantly by patients' race, body weight, smoking habits, and histological subtypes, suggesting that environmental and demographic factors modulate ASPM expression, or that ASPM expression reflects different biological subtypes of the disease associated with these characteristics.
Cell cycle network involvement. ASPM's top correlated proteins included BUB1, CCNA2, CDC20, CDK1, and TTK -- several of which overlap with CDC20's interaction network -- and KEGG analysis showed primary enrichment in cell cycle pathways. The shared network with CDC20 suggests these two genes cooperate in driving cell division and may represent a coordinated pathway of cancer cell proliferation.
Selective immune checkpoint correlation. While CDC20 coexpressed with all five immune checkpoints analyzed, ASPM showed significant coexpression with CD274 (PD-L1), PDCD1LG2 (PD-L2), and TOX, but not with PDCD1 (PD-1) or CTLA4. ASPM was also associated with CD8+ T cell, neutrophil, and dendritic cell infiltration patterns in bladder cancer, linking spindle assembly dysfunction to specific aspects of the tumor immune microenvironment.
Gene silencing in T24 bladder cancer cells. To validate the functional importance of CDC20 and ASPM beyond computational predictions, the researchers knocked down each gene's expression in the T24 bladder cancer cell line using small interfering RNA (siRNA). Cells transfected with siASPM or siCDC20 were compared to cells receiving a control siRNA.
Proliferation was significantly reduced. Cell Counting Kit-8 (CCK-8) assays measured cell viability every 24 hours after knockdown. Both siASPM and siCDC20 groups showed significantly reduced cell viability compared to the siControl group, confirming that these genes actively promote bladder cancer cell proliferation rather than simply being incidentally overexpressed.
Colony formation was impaired. Clone formation assays, which measure a cell's ability to multiply and form visible colonies from a single cell over two weeks, showed that knockdown of either ASPM or CDC20 substantially reduced the number and size of colonies formed. This provides complementary evidence that both genes are functionally required for the self-renewal and expansion capacity that defines cancer cell behavior.
From bioinformatics to biology. The transition from computational prediction to experimental validation is a critical step in biomarker discovery. By demonstrating that silencing CDC20 and ASPM in actual bladder cancer cells reduces proliferation, the study moves beyond association to establish a causal role for these genes in bladder cancer cell growth.
Biomechanics pathways link to invasion. The enrichment of DEGs in muscle contraction, cytoskeleton organization, and focal adhesion pathways reflects the importance of cellular biomechanics in bladder cancer. Cancer cell deformability -- governed by cytoskeletal dynamics -- is a key enabler of invasion and metastasis, allowing tumor cells to squeeze through tissue barriers and enter the bloodstream or lymphatic system.
CDC20's immune checkpoint connections. The finding that CDC20 coexpresses with all five analyzed immune checkpoint genes was unexpected and potentially important. Immune checkpoints like PD-1/PD-L1 and CTLA4 suppress anti-tumor immune responses, and their coexpression with a cell cycle regulator like CDC20 suggests a link between tumor proliferative activity and immune escape -- fast-dividing tumors may simultaneously upregulate both growth and immune evasion programs.
TOX as an emerging immunotherapy target. Among the immune genes correlating with both CDC20 and ASPM, the TOX transcription factor is particularly notable. TOX has been identified as a key driver of T cell exhaustion, and three consecutive Nature articles around the time of this paper established TOX's central role in tumor immunotherapy. The correlation between CDC20, ASPM, and TOX suggests these cancer genes may contribute to immune cell exhaustion in the bladder tumor microenvironment.
Therapeutic potential. If CDC20 and ASPM drive both proliferation and immune evasion, they represent candidates for dual-targeting strategies that could simultaneously reduce tumor growth and restore immune surveillance. Inhibitors of CDC20 (which acts as an activator of the anaphase-promoting complex) have been explored in other cancers and may deserve investigation as therapeutic agents or combination targets with checkpoint inhibitors in bladder cancer.
Dual-function biomarker discovery. This study identified CDC20 and ASPM as bladder cancer genes that are simultaneously prognostic (high expression predicts worse survival) and potentially predictive for immunotherapy response (based on immune checkpoint coexpression patterns). Biomarkers that serve both functions are particularly valuable clinically, as they can guide both treatment selection and prognosis counseling.
Multi-method validation approach. The rigorous pipeline -- requiring consistency across three independent datasets, consensus hub gene identification by four algorithms, survival analysis, immune correlation analysis, and wet-lab experimental validation -- provides multiple layers of evidence supporting CDC20 and ASPM as genuine bladder cancer biomarkers rather than statistical artifacts.
Potential immunotherapy targets. Beyond their use as biomarkers, CDC20 and ASPM may represent novel immunotherapy targets. Their coexpression with PD-L1 and TOX suggests that tumors with high CDC20 or ASPM expression may be particularly responsive to PD-1/PD-L1 checkpoint inhibitors, and future clinical studies could test whether these gene expression levels predict immunotherapy response in bladder cancer patients.
Foundation for future research. The data presented provide a computational and experimental foundation for further investigation of CDC20 and ASPM in bladder cancer clinical samples, animal models, and ultimately clinical trials. Understanding how these cell cycle genes interact with the immune system may open new therapeutic windows in a disease where treatment progress has been frustratingly slow.